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Abstract
Background: Severe familial hypercholesterolemia (FH) individuals, refractory to conventional lipid-
lowering medications are at exceptionally high risk of cardiovascular events. The established therapeutic 
option of last choice is lipoprotein apheresis (LA). Herein, it was sought to investigate the clinical use-
fulness of LA in a highly selected group of severe heterozygous FH (HeFH), as recently described by the 
International Atherosclerosis Society (IAS), for their efficacy in lipid reduction and safety.
Methods: Efficacy and safety of LA were investigated in 318 sessions of 7 severe HeFH females with 
cardiovascular disease, over a mean period of 26.9 ± 6.5 months. Relative reduction of low density lipo-
protein cholesterol (LDL-C) ≥ 60%, clinical complications and vascular access problems were evaluated 
and compared between the direct adsorption of lipoproteins (DALI) and lipoprotein filtration (Mem-
brane Filtration Optimized Novel Extracorporeal Treatment [MONET]). Additionally, lipoprotein (a)  
[Lp(a)], total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and 
fibrinogen concentrations were investigated. 
Results: The relative reduction of LDL-C, TC, TG and Lp(a) were 69.4 ± 12.9%, 59.7 ± 9.1, 51.5 ±  
± 14.2% and 71.3 ± 14.4%, respectively. A similar efficacy was found in both systems in LDL-C re-
moval. DALI system led to larger depletions of Lp(a) (80.0 [76–83]% vs. 73.0 [64.7–78.8]%; p < 0.001). 
The frequency of clinical side effects and vascular access problems were low (8.5%). 
Conclusions: Long-term LA in severe HeFH individuals is safe and efficiently reduces LDL-C and 
Lp(a). Higher efficacy of the DALI system than MONET in Lp(a) removal may indicate the need for in-
dividualized application of the LA system in severe HeFH individuals. (Cardiol J 2019; 26, 6: 669–679)
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Introduction
Severe familial hypercholesterolemia (FH) 
patients are at exceptionally high risk of car-
diovascular disease (CVD) [1]. Although some 
authors have suggested that individuals with het-
erozygous FH (HeFH) and untreated low-density 
lipoprotein cholesterol (LDL-C) greater than 309 
mg/dL suffer from severe HeFH, the definition 
of severe phenotype of FH was not clear [2]. Re-
cently, the International Atherosclerosis Society 
(IAS) considered not only initial LDL-C values, 
but also the presence of risk conditions, as well 
as clinical or advanced subclinical atherosclerotic 
CVD [2–7]. These high-risk conditions proposed 
by IAS include diabetes, arterial hypertension, 
smoking history, chronic kidney disease, positive 
family history of early CVD in first-degree relative, 
low high-density lipoprotein cholesterol (HDL-C) 
and elevated lipoprotein (a) [Lp(a)]. Among high 
risk features special attention should be directed 
to increased Lp(a) with its strong atherogenic and 
thrombogenic effect, and resistance to conventional 
lipid-lowering medications [5, 8]. Individuals with 
severe phenotype of FH often do not adequately 
respond to high-intensity lipid-lowering medica-
tions and do not achieve treatment goals [9]. The 
recommended target level for severe FH indi-
viduals for secondary prevention is LDL-C below 
70 mg/dL [9]. Thus, more aggressive forms of 
therapy might be beneficial in severe FH to ar-
rest the progression of atherosclerosis and reduce 
cardiovascular event rate [10–12]. The treatment 
option in severe FH widely used since the 80s has 
been long-term lipoprotein apheresis (LA) [13, 
14]. LA is an extracorporeal technique of selective 
removal of lipoproteins. Various lipoprotein apher-
esis systems are routine in clinical use currently. 
Whole blood adsorption of lipoproteins includes 
direct adsorption of lipoproteins with polyacrylamide 
(DALI) and dextran sulfate cellulose adsorption. 
Atherogenic lipoproteins may also be eliminated 
in following primary plasma separation methods: 
lipoprotein filtration (MONET), heparin-induced 
extracorporeal LDL-C precipitation (HELP), silicate 
gel adsorption, immunoadsorption (IMA) and dex-
tran sulfate cellulose [15]. LA procedures need to be 
repeated every 1–2 weeks due to LDL-C and Lp(a) 
level rebound effect. All LA techniques have been 
shown to effectively reduce LDL-C along with Lp(a) 
concentrations by more than 60%, while being well 
tolerated in long-term application. LDL-apheresis 
treatment also exerts a pleiotropic effect, improv-
ing rheological properties of the blood and reducing 
inflammatory markers [16, 17]. Regular apheresis 
sessions have been proved to slow the progres-
sion of atherosclerosis and reduce the incidence of 
cardiovascular events [12, 18–20]. The main goal 
of LA treatment in HeFH is to achieve an LDL-C 
reduction ≥ 60% at each therapeutic session [21]. 
Additionally, time-averaged LDL-C less than 
100 mg/dL might be considered as a goal [21].
Although data confirming the effectiveness 
and safety of lipoprotein apheresis have been 
published, the studies often aggregated patients 
with undefined hypercholesterolemia, homozygous 
FH, HeFH and isolated increased Lp(a), treated 
with various apheresis systems and differing lipid-
lowering medication regimens [22, 23]. This lack 
of stratification by type of dyslipidemia resulted in 
misleading findings. Therefore, the main purpose of 
the current research was to investigate the clinical 
usefulness of lipoprotein apheresis in a highly se-
lected group of severe HeFH, according to the IAS 
definition, for their efficacy in lipid reduction and 
safety. Additionally, the safety and effectiveness of 
DALI and MONET systems were compared in the 
current study group. 
Methods
The study was carried out prospectively in 
a large Polish lipoprotein apheresis center, es-
tablished at the First Department of Cardiology, 
Medical University of Gdansk, following the Good 
Clinical Practice guidelines. Researchers obtained 
written informed consent before patient inclusion, 
in accordance with the Declaration of Helsinki. All 
treatment protocols and medical records for each 
patient undergoing LA were reviewed, except for 
initial sessions in the first month of treatment.
Patients 
The primary indication to LA treatment was 
HeFH with symptomatic CVD and LDL-C concen-
tration of more than 160 mg/dL despite maximally 
tolerated intensive lipid-lowering medications [14]. 
Seven female patients with definite FH according 
to the modified Dutch Lipid Network Criteria and 
confirmed a mutation in LDLR or APOB gene, 
fulfilling the criteria of severe FH by the IAS, 
were enrolled into the study [4, 24]. At the initia-
tion of LA treatment, all patients had a history of 
a documented CVD and at least three additional high 
risk-features for severe FH. All individuals were 
treated with rosuvastatin in a dose of 40 mg daily 
with or without ezetimibe 10 mg daily by more than 
12 months before starting LA and continued such 
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treatment on apheresis. The mean age of patients 
at the start of LA therapy was 54.5 ± 5.5 years. 
Detailed clinical and biochemical characteristics 
of investigated patients are presented in Table 1.  
Lipoprotein apheresis 
Lipoprotein apheresis sessions (n = 318) 
were performed in weekly or biweekly intervals 
using two techniques, according to patient charac-
teristics over a period of 37 months. Concomitant 
angiotensin converting enzyme inhibitors (ACEI) 
therapy was a contraindication to DALI treatment. 
LA therapy was started 6.0 ± 1.5 years after the 
clinical diagnosis of FH. 162 DALI sessions with 
large adsorber configurations (DALI 1000, DALI 
1250) and 156 MONET procedures were performed 
over a mean period of 26.9 ± 6.5 months [25]. To 
provide adequate effectiveness, at least 1.5 of blood 
volume was processed during DALI therapeutic 
sessions, and at least 45 mL of plasma volume/kg 
was treated during MONET sessions [26]. Both 
acid citrate dextrose (ACD-A) and heparin in the 
priming solution were used as an anticoagulant. Ar-
teriovenous (AV) fistula was established as access 
in all patients due to the insufficiency of peripheral 
venous access. Initial sessions in the first months 
and procedures interrupted before expected blood/ 
/plasma volume purification were excluded from 
the final analysis of biochemical parameters. 
Biochemical parameters
All biochemical parameters were measured 
in one laboratory at scheduled intervals. LDL-C 
levels were subsequently calculated using the 
Friedewald formula unless triglycerides (TG) were 
above 400 mg/dL. Acute reduction in total choles-
terol (TC), LDL-C, HDL-C, TG, Lp(a) and fibrino-
gen were calculated from pre- and post-apheresis 
results. The time-averaged mean LDL-C level 
was calculated according to the formula devised 
by Kroon, where CMAX and CMIN are defined as the 
immediate pre- and post-treatment values: CAVG = 
CMIN + 0.73 × CMAX – CMIN [27]. The effectiveness 
of LA was expressed as an achievement of acute 
post-apheresis LDL-C reduction by more than 60%. 
Alternatively, the time-averaged LDL-C below 
100 mg/dL was a goal of treatment. Additionally, 
HDL-C, TC, TG, Lp(a) and fibrinogen reductions 
were investigated. 
Side-effects
Clinical complications and vascular access 
problems were investigated at each therapeutic 
apheresis session. Clinical complications were Ta
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specified as follows: hypotension with systolic blood 
pressure < 90 mmHg and accompanying symptoms 
(paleness, nausea), hypocalcemia, oedema, severe 
bleeding, anemia, and thrombocytopenia. Vascular 
complications included puncture problems, hema-
toma, bleeding and stenosis of AV fistula.
Statistical analysis 
Continuous data were presented as a mean 
value and standard deviation (SD) or as a median 
and interquartile range (IQR) or as a median and 
minimum and maximum value. Categorical data 
were presented as percentages. Normal distribu-
tion was verified by the Kolmogorov-Smirnov test. 
Continuous data were compared by the Student 
t-test or U-Mann Whitney test depending on the 
distribution. Categorical data were compared by 
the c2 test and Fisher exact test. P value less than 
0.05 was considered statistically significant. Data 
were analyzed using SPSS software v.21 (IBM, 
Chicago, Illinois, USA).
Results 
Lipoprotein apheresis 
The mean duration time of the procedure was 
140.0 (60–240) min. ACD-A was used in a mean 
volume of 329.8 ± 134.9 mL, with the ratio of cit-
rate: blood ranging from 1:20 to 1:40 in both DALI 
and MONET. DALI sessions were significantly 
shorter than MONET (130.0 [120–140] vs. 170.0 
[158.0–183.7]; p < 0.001) with less ACD-A con-
sumption (244.0 [215–302] vs. 431.0 (374.5–486.5); 
p < 0.001). Average blood volume processed 
during DALI sessions was 8540 ± 155 mL. 
During MONET sessions average plasma volume 
2903.5 ± 867.1 mL was achieved. 
Cholesterol, lipoprotein (a) and fibrinogen 
Laboratory parameters before and during 
chronic LA treatments are summarized in Table 2. 
Mean pre-apheresis values of TC and LDL-C 
were high (308.9 ± 94.1 and 222.8 ± 89.5 mg/dL, 
respectively). Apheresis reduced both lipids 
acutely to 121.6 ± 39.3 mg/dL and 68.8 ± 37.6 
mg/dL, respectively.  Mean pre-apheresis values of 
HDL-C were below the normal range for females 
(42.5 ± 10.1 mg/dL). Apheresis reduced HDL-C 
to a lesser extent than other lipids (22.7 ± 10.9%). 
Apheresis sessions removed TG by 51.5 ± 14.2% 
in the mean, starting from 220.8 ± 162.7 mg/dL. 
Apheresis session led to acute depletion of Lp(a) 
from pre-apheresis concentration of 0.5 ± 0.4 g/L 
to 0.12 ± 0.09 g/L. Fibrinogen was reduced by 
Table 2. Lipoprotein apheresis — biochemical parameters.
Mean ± SD Median Minimum Maximum
TC pre-apheresis [mg/dL] 308.9 ± 94.1 294.0 153.0 569.0
TC post-apheresis [mg/dL] 121.6± 39.3 114.0 62.0 354.0
TC [% reduction] 59.7 ± 9.1 61.5 32.4 78.9
LDL-C pre-apheresis [mg/dL] 222.8 ± 89.5 207.5 54.0 490.0
LDL-C post-apheresis [mg/dL] 68.8 ± 37.6 66.0 1.0 177.0
LDL-C [% reduction] 69.4 ± 12.9 71.8 17.3 98.3
Interval LDL-C [mg/dL] 181.4 ± 72.8 154.9 40.0 395.8
HDL-C pre-apheresis [mg/dL] 42.5 ± 10.1 41.0 15.0 75.0
HDL-C post-apheresis [mg/dL] 32.4 ± 6.8 32.0 11.0 53.0
HDL-C [% reduction] 22.7 ± 10.9 21.7 0.0 62.16
TG pre-apheresis [mg/dL] 220.8 ± 162.7 157.0 46.0 1121.0
TG post-apheresis [mg/dL] 103.8 ± 84.8 72.0 23.0 616.0
TG [% reduction] 51.5 ± 14.2 53.2 10.8 83.6
Lp(a) pre-apheresis [g/L] 0.5 ± 0.4 0.39 0.08 1.37
Lp(a) post-apheresis [g/L] 0.12 ± 0.09 0.09 0.01 0.57
Lp(a) [% reduction] 71.3 ± 14.4 76.1 21.4 94.1
Fibrinogen pre-apheresis [mg/dL] 3.25 ± 0.63 3.25 2.2 6.47
Fibrinogen post-apheresis [mg/dL] 1.96 ± 0.77 2.02 0.63 3.96
Fibrinogen [% reduction] 39.7 ± 21.2 45.6 2.8 76.0 
Data are presented as mean ± standard deviation (SD) and median with minimum and maximum. Abbreviations — see Table 1.
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39.7 ± 21.2% starting from the pre-apheresis level 
of 3.25 ± 0.63 mg/dL (Table 2).
DALI vs. MONET 
Higher pre- and post-apheresis TC, LDL-C, 
HDL-C and Lp(a) concentrations in MONET 
sessions vs. DALI (Table 3) were observed. In 
contrast, the pre- and post-apheresis TG levels 
were higher in patients treated by DALI system, 
compared to MONET (Table 3). MONET system 
led to higher TC and HDL-C reductions, compared 
to DALI (Fig. 1).
The pre-apheresis concentrations of fibrinogen 
were similar in DALI and MONET groups. In com-
parison to MONET, DALI treatment led to a lower 
removal of fibrinogen (62.5 [52.1–68.0]% vs. 19.8 
[13.9–25.2]%; p < 0.001) (Fig. 1). Post-apheresis 
fibrinogen concentration in MONET sessions was 
below normal range (1.15 [1.00–1.52] mg/dL).  
Analyzing all LA therapeutic sessions, the 
relative reduction of LDL-C up to 69.4 ± 12.9% 
(71.8 [17.3–98.3]%) was achieved. Comparing both 
systems, their similar efficacy was found (72.6 
[66.5–83.5]% vs. 74.1 [69.9–77.9]%; p = 0.809) 
(Fig. 2). A large number of LA sessions resulted 
in at least a 60% reduction of LDL-C (82% of DALI 
treatments and 78% of MONET treatments). 
Calculated time-averaged LDL-C was 181.4 ± 
± 72.8 (154.9 [40–395.8]) mg/dL. The DALI 
system resulted in the achievement of a lower 
time-averaged LDL-C, than MONET (113.4 vs. 
228.5 mg/dL; p < 0.001). 
The acute reduction of Lp(a) of 71.3 ± 14.4% 
(76.1 [21.4–94.1]%) was achieved. It was observed 
that DALI system was more efficient in relative 
removal of Lp(a) than MONET (80.0 [76–83]% vs. 
73.0 [64.7–78.8]%; p < 0.001) (Fig. 2).
Additional analysis revealed that 54% of all 
sessions resulted in a post-apheresis LDL-C of 
less than 70 mg/dL. A higher percent of DALI vs. 
MONET sessions resulted in decreasing LDL-C 
below 70 mg/dL (88% vs. 32%). 
Side effects
The total incidence of clinical side effects was 
low (8.5%). Major complications were observed in 
2 cases of DALI treatment. One episode of brady-
kinin syndrome (hypotension, flush, bradycardia 
and dyspnea) with Quincke odema and lumbar 
pain was observed. The patient was switched to 
MONET system. Heparin-induced thrombocyto-
penia (HIT) with thrombosis in extracorporeal 
system appeared in another individual. Heparin 
was replaced by fondaparinux and DALI treatment 
was continued.  
The total incidence of hypotension, vascular 
problems, and hypocalcemia was low (7.5%, 6.12%, 
1.7%, respectively). However, the frequency of 
complications related to vascular access was higher 
in MONET sessions vs. DALI (10.5% vs. 1.4%, 
Table 3. Biochemical parameters in DALI versus MONET system.
DALI MONET P 
TC pre-apheresis [mg/dL] 238.0 (207–295) 372.0 (254.5–409.5) < 0.001
TC post-apheresis [mg/dL] 100.0 (83–121) 114.0 (101.5–134.5) 0.003
TC [% reduction] 58.8 (54.8–64.5) 65.6 (61.2–69.7) < 0.001
LDL-C pre-apheresis [mg/dL] 141.0 (122–170) 286.0 (191.5–326.5) < 0.001
LDL-C post-apheresis [mg/dL] 37.5 (26–57) 69.0 (49.5–88.0) < 0.001
LDL-C [% reduction] 72.6 (66.5–83.5) 74.1 (69.9–77.9) 0.8
Interval LDL-C [mg/dL] 113.4 (96.9–137.5) 228.5 (155.6–260.3) < 0.001
HDL-C pre-apheresis [mg/dL] 36.0 (34–39) 50.0 (42.5–58.0) < 0.001
HDL-C post-apheresis [mg/dL] 31.0 (28.2–34.0) 36.0 (30.0–40.0) < 0.001
HDL-C [% reduction] 14.3 (9.5–20.6) 30.3 (25.7–34.2) < 0.001
TG pre-apheresis [mg/dL] 285.0 (184–383) 132.0 (104.0–185.0) < 0.001
TG post-apheresis [mg/dL] 126.50 (73–198) 63.0 (49.5–81.5) < 0.001
TG [% reduction] 51.81 (45.2–62.2) 54.4 (44.3–62.6) 0.9
Lp(a) pre-apheresis [g/L] 0.43 (0.22–0.72) 0.77 (0.35–1.09) 0.001
Lp(a) post-apheresis [g/L] 0.08 (0.04–0.13) 0.17 (0.12–0.24) < 0.001
Lp(a) [% reduction] 80.0 (76–83) 73.0 (64.7–78.8) < 0.001
Data are presented as median (interquartile range [IQR]). Abbreviations — see Table 1.
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p = 0.001). Mild, transient hypotension occurred 
with similar frequency in DALI and MONET (4.9% 
vs. 9.9%, p = 0.12). Administration of crystalloid 
infusion before and during apheresis substantially 
reduced the frequency of symptomatic hypoten-
sion. Blood flow at the start and the end of pro-
cedures was not related with the incidence of 
hypotension (Table 4). Hypocalcemia incidence 
rate was similar during MONET sessions (3.3% vs. 
0%, p = 0.06). Anemia occurred in one individual 
undergoing DALI and one treated by MONET 
system. Angina episodes were not recorded, as 
well as abdominal pain.
Discussion
The study was undertaken to assess the effi-
cacy and safety of lipoprotein apheresis in  a highly 
selected group of severe FH individuals, by IAS 
definition. Investigated patients presented a pat-
tern of severe HeFH with an advanced CVD, high 
LDL-C at initial presentation (> 310 mg/dL) and at 
least three additional high-risk features. Increased 
Lp(a) level greater than 50 mg/dL was present in 
more than half of them (4/7) [28]. Administration 
of high-intensity oral lipid-lowering agents failed to 
reduce LDL-C below 160 mg/dL. Although cardio-
vascular risk in HeFH is largely driven by chronic 
exposure to elevated LDL-C, cardiovascular risk 
factors in HeFH are additive, indicating very high 
CVD risk in the present cohort. Therefore, treat-
ment strategy should be aggressive, targeting an 
ideal goal of LDL-C below 70 mg/dL. In the current 
study, LDL-C was acutely reduced from 223 mg/ 
/dL to 69 mg/dL, which corresponded to a relative 
reduction of 69%. Relative decreases of LDL-C 
greater than 60% was reached in a large number of 
treatments (close to 80%) indicating a good quality 
of treatment. In LDL-Apheresis Atherosclerosis 
Regression Study (LAARS) the achieved acute 
63% reduction in LDL-C led to the angiographic 
Figure 1. Reduction of total cholesterol (TC), high den-
sity lipoprotein cholesterol (HDL-C) and fibrinogen in 
DALI vs. MONET. Data are presented as median and 
interquartile range.
Figure 2. Reduction of low density lipoprotein cholester-
ol (LDL-C) and lipoprotein (a) [Lp(a)] in DALI vs. MONET. 
Data are presented as a median and interquartile range.
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Table 4. Influence of crystalloid infusion on hypotension during lipoprotein apheresis (LA) treatment.
Symptomatic hypotension 
during apheresis (n = 22)
Apheresis session without  
hypotension (n = 272)
P
Crystalloid infusion 14 (63.63%) 54 (19.85%) < 0.001
Crystalloid infusion before procedure 8 (36.36%) 39 (14.34%) 0.01
Crystalloid infusion during procedure 9 (40.91%) 20 (7.35%) < 0.001
Blood flow at start of LA [mL/min] 52.86 ± 9.16 50.81 ± 8.71 0.3
Blood flow 2 at the end of LA [mL/min] 96.00 ± 29.00 101.17 ± 20.25 0.4
Data for blood flow are presented as mean ± standard deviation.
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arrest of the progression of coronary artery disease 
in a majority of patients treated with simvastatin 
and biweekly LA [29]. Other studies carried out in 
HeFH, on various systems of apheresis reported 
55–70% mean LDL-C reduction [21, 30, 31]. Nev-
ertheless, it was found that post-apheresis LDL-C 
values were below 70 mg/dL only in 54% of LA 
sessions. When DALI and MONET systems were 
compared, single DALI sessions achieved LDL 
below 70 mg/dL more often when compared to 
MONET (88% vs. 32%). These results may be 
easily explained by higher pre-apheresis LDL-C 
observed in patients treated with MONET as 
compared to DALI. Premature discontinuation of 
MONET sessions due to adverse events decreased 
the percent of efficacious LA sessions, compared 
to other reports [31]. Last but not least, the staff 
and site experience are a known factor influencing 
the course of LA sessions [32].
Considering the achievement of a time-av-
eraged LDL-C below 100 mg/dL as a goal of LA 
therapy, it was out of range in the present study 
(181 mg/dL). However, it agrees with previous 
studies. In a large study of 118 patients treated 
by LA in Dresden, the time-averaged LDL-C was 
119.8 mg/dL, similar to the present DALI patients. 
It may be explained by lower pre-apheresis LDL-C 
in the Dresden group, than the cohort herein 
(148.8 mg/dL vs. 223 mg/dL) [33]. 
The mean reduction of Lp(a) observed in this 
study was close to 70%. DALI treatment led to 
larger depletion of Lp(a) than MONET. Ramlow et 
al. [31] showed equal Lp(a) removal and slightly 
better efficacy of LDL-C removal for DALI treat-
ment than MONET. It is suspected that a more 
efficient removal of Lp(a) in the present DALI 
system might be an effect of an application of larger 
adsorbers (DALI 1000 and 1250) or higher blood 
volume processed. However, there are other fac-
tors determining the acute lipoprotein reduction 
in DALI-apheresis such as weight, height, pre-
apheresis lipid levels, as well as blood flow rate 
through the adsorber.
The present findings also confirmed that 
direct adsorption and lipoprotein filtration varied 
in selectivity. MONET substantially reduced fi-
brinogen concentration, which may improve blood 
viscosity and its rheological properties. Bleeding 
complications were not reported, even though 2 pa-
tients were administrated with oral anticoagulants. 
MONET system led to slightly higher HDL-C re-
duction compared to DALI. However, the reduction 
was lower, than other lipids. Thus, results agree 
with previous reports [31].
A mean rate of side effects of 8.5% was ob-
served, which is in the line with data from a large 
study by Dittrich-Riediger et al. [33]. Serious AE 
were incidental as in previous reports [34]. Despite 
ACEI cessation before DALI initiation, bradykinin 
syndrome was reported in the present study. An-
other patient treated by DALI was affected by HIT. 
DALI system is known to cause bradykinin release 
with peaks at 1000–2000 mL of treated blood volume 
and ACEI block bradykinin degradation into inactive 
metabolites. Thus, they are contraindicated in pa-
tients treated by DALI system. Angiotensin receptor 
blockers may be administrated, as in the present 
case. HIT is an extremely rare complication of LA. 
However, some authors reported thrombocytopenia 
previously. The most frequently observed complica-
tions of lipoprotein apheresis in the present study 
were vascular access problems and hypotension, 
as previously reported by other authors [33, 35]. 
A higher incidence of vascular access problems was 
found  compared to other studies [23]. In a large 
multicenter, prospective study of German patients 
undergoing DALI and MONET apheresis, Kozik-
Jaromin et al. [35] reported 27 puncture problems 
in 3451 sessions [35]. However, hematoma and 
bleeding as problems with vascular access were 
also reported herein. Otherwise, some data indicate 
an increased rate of venous puncture problems 
were found in female vs. male patients [33]. All 
investigated individuals in the present cohort were 
females. Secondly, the type of the vascular access 
determined issues with its maintenance. Access-
ing peripheral veins might be the best option for 
lipoprotein apheresis treatment [36]. In the United 
Kingdom analysis of peripheral vein cannulation 
represented even 79% of initial vascular access 
strategies with AV fistula use accounting for 15%, 
with a trend to AV cannulation [37]. Unfortunately, 
due to unavailability of large veins for repeated 
puncture, arteriovenous fistulas were established 
in all patients of the present study. Detailed analysis 
showed that 1 patient undergoing MONET suffered 
from recurrent stenosis and thrombosis of arterio-
venous fistula. Kozik-Jaromin et al. [35] excluded 
the first 3 months of treatment from analysis, not 
only the first month of treatment as in the present 
study. Increased rate of AE during all 12 months of 
treatment was observed in previous reports.
Mild, transient hypotension, mainly caused 
by initial “blood donation” into the extracorporeal 
circuit, occurred with 7.5% frequency. The Ger-
man Registry of Lipoprotein Apheresis (GLAR) 
showed a lower rate of hypotension of 1.09–1.28% 
[21]. However, as demonstrated herein, hypoten-
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sion may be avoided by crystalloid infusion to the 
contralateral vein before and during an apheresis 
session. Some authors have described routine 
intravenous administration of saline or HAES at 
apheresis session initiation, and this may have 
been the reason for this difference. Symptomatic 
hypocalcemia caused by citrate infusion was rare 
in the present study. Oral supplementation of 
calcium prior to a DALI session was introduced in 
susceptible patients, as well as routine optimiza-
tion of ACD-A. 
Long-term LA with efficient LDL-C and Lp(a) 
removal was a consequence to improvement of the 
CVD course in the patients studied. The incidence 
of major adverse cardiac events (MACE; defined 
as cardiovascular death, non-fatal acute coronary 
syndrome and repeat coronary revascularization) 
decreased after LA initiation. MACE rate was 
reduced from 41 events before LA inception to 
8 during the period of LA treatment. The positive 
impact of LDL apheresis on cardiovascular morbi-
dity in individuals with hypercholesterolemia has 
been previously confirmed in several observational 
trials [38]. Sampietro et al. [39] reported a significa-
nt reduction of adverse cardiac or vascular events 
in 30 individuals with FH or familial combined 
hypercholesterolemia and CVD. Adverse cardiac 
or vascular events incidences occurred prior and 
after LA treatment inception, which were 86 and 
15 events, respectively [39]. 
According to available research, this is the 
first report focused on the most severe phenotype 
of HeFH refractory to an equal regimen of statin 
(rosuvastatin 40 mg daily) at particularly high car-
diovascular risk. All patients were female. Thus, 
gender influence on cardiovascular risk can be 
omitted. LA in the present study was carried out 
and documented by one physician at a specialized 
apheresis center. The treatment and observation 
period were long.
Study results highlight the importance of more 
aggressive forms of treatment such as LA in severe 
HeFH individuals with advanced CVD, additional 
high-risk features, and LDL-C greater than 160 
mg/dL, despite high-intensity statin therapy. The 
present findings also point to the fact that despite 
LA there was a substantial unmet need for novel 
schedules of treatment to control LDL-C in those 
individuals [4]. In further studies on cardiovascular 
outcome in real-world practice, it might be inter-
esting to clarify if severe HeFH individuals with 
CVD and increased Lp(a) concentration benefit 
from DALI treatment with large adsorbers (1000 
or 1250) in combination with novel drugs [40].
Limitations of the study
The present study is small in size, which was 
caused by a low number of HeFH patients treated 
by lipoprotein apheresis in Poland. Despite an 
increase in the proportion of patients treated with 
strong statins in recent years, treatment goals 
in hypercholesterolemia are not being achieved 
[41]. Based on the prevalence of severe FH eli-
gible to LA of 2.4% and approximately 1000 FH 
individuals with molecular confirmation in Poland 
(unpublished data), it is estimated that there are 
24 severe HeFH, of which 7 are currently being 
treated with LA [42].
Conclusions
Long-term LA in severe HeFH individuals 
is safe and efficiently reduces LDL-C and Lp(a). 
Higher efficacy of DALI system vs. MONET in 
Lp(a) removal may indicate a need for individual-
ized application of LA system in severe HeFH 
individuals.
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